EP0585224A1 - ANTICORPS MONOCLONAUX QUI SE LIENT A L'IgE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IgE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES - Google Patents

ANTICORPS MONOCLONAUX QUI SE LIENT A L'IgE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IgE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES

Info

Publication number
EP0585224A1
EP0585224A1 EP92901974A EP92901974A EP0585224A1 EP 0585224 A1 EP0585224 A1 EP 0585224A1 EP 92901974 A EP92901974 A EP 92901974A EP 92901974 A EP92901974 A EP 92901974A EP 0585224 A1 EP0585224 A1 EP 0585224A1
Authority
EP
European Patent Office
Prior art keywords
ige
tesc
tes
cells
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92901974A
Other languages
German (de)
English (en)
Other versions
EP0585224A4 (en
Inventor
Tse Wen Chang
Frances M. Davis
Lani A. Gossett
Lee K. Sun
Bill N. C. Sun
Cecily R. Y. Sun
Ruey S. Liou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of EP0585224A1 publication Critical patent/EP0585224A1/fr
Publication of EP0585224A4 publication Critical patent/EP0585224A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • immediate-type hypersensitivities such as extrinsic asthma, hay fever, and allergic responses to certain foods or drugs, are mediated
  • the allergen binds to the IgE which is bound to receptors on the surfaces of mast cells and basophilic leukocytes (basophils).
  • the binding of the allergen causes cross-linking of the surface IgE molecules and hence the underlying receptors (FceR) for the Fc portion of IgE, thereby triggering the release of pharmacologic mediators such as histamine, the slow-reacting substance of anaphylaxis (SRA), and serotonin.
  • SRA slow-reacting substance of anaphylaxis
  • IgE is secreted by a particular class of B cells, which also express IgE on their surface. In individuals sensitized to specific allergens, the allergen-
  • the immune system's regulatory, cytolytic or cytotoxic mechanisms can be used to suppress or destroy the B cells which are bound by monoclonal antibodies. Other immune mechanisms can eliminate the secreted IgE which is bound by the monoclonal antibodies.
  • IgE binds to the FceR receptors on the surface of basophils and mast cells very strongly, with an association constant, Ka, of about 1 x 10 10 liter/mole. Even though IgE is not synthesized by basophils and mast cells, the very strong and stable association of IgE with FceR means that IgE is virtually always present and exposed on the surface of these ceils. Thus, an immunotherapeutic agent which targets IgE must not react with the IgE on basophils and mast cells, in order to avoid cross-linking this IgE and the underlying FceR and thereby triggering an allergic reaction.
  • TES-C21 is a murine monoclonal antibody
  • TESC-2 is a chimeric mouse/human mAb with its variable regions derived from TES-C21, and with human ( ⁇ l, K) constant regions.
  • Both TES-C21 and TESC-2 bind specifically to IgE and are not reactive with
  • Both mAbs bind to IgE secreting B cells, and neither induces histamine release from human basophils. Both mAbs also inhibit the binding of IgE to the low affinity FceRII receptor, which is present on B cells producing all of the various heavy chain isotypes.
  • these mAbs will bind specifically to secreted IgE, and the secreted IgE can then be eliminated by the immune system. They also bind specifically to IgE expressed on the surface of IgE-producing B cells, and these B cells
  • Fig. 1 shows a comparison of the binding of TES-C21 and TESC-2 to
  • IgE which is bound to microtiter plates.
  • Fig. 2 shows a comparison of the relative affinity of the binding of TES-C21 and TESC-2 to IgE which is bound to microtiter plates.
  • Fig.3 shows a comparison of the binding of TES-C21 and TESC-2 to
  • Fig. 4 shows a comparison of the inhibition of the binding of IgE to FceRII by TES-C21 and TESC-2.
  • the epitopes targeted by the TES-C21 and TESC-2 mAbs are unique in that they are present on IgE bearing B lymphocytes but not on mast cells or basophils. The epitopes are believed to be located at or near the binding site for FceR, and to be obscured when IgE is bound to FceR on basophils and mast cells. These mAbs are specific for the IgE-secreting B cells, and did not bind to B cell lines secreting other Ig isotypes, to a T cell line or a
  • the TES-C21 and TESC-2 mAbs also do not bind to IgE on the low affinity FceRII receptors on B cells, thereby reducing the destruction or regulation of B cells which produce isotypes other than IgE.
  • the TES-C21 and TESC-2 mAbs can be used in any way in which the mAbs described in published International Application PCT/US88/04706 can be used. These uses include diagnostic uses such as identifying and enumerating IgE-bearing B cells in mixed leukocyte populations, and
  • TESC-2 chimeric TESC-2 mAb
  • the mAbs can be systemically administered, preferably intravenously or intramuscularly, as free antibodies to patients afflicted with IgE-mediated allergy in amounts sufficient to down-regulate or eliminate IgE-producing cells, and/or amounts sufficient to bind to secreted IgE.
  • TESC-2 is of IgGl subclass, and therefore mediates antibody dependent cellular cytotoxicity ("ADCC") of B cells expressing IgE on their surface. These IgE-expressing B cells also secrete IgE. Therefore, TESC-2
  • TES-C21 could also be used to down-regulate B cells producing IgE through other regulatory immune mechanisms.
  • TES-C21 and TESC-2 can be used for in vivo therapeutic applications, they may also be used in extra-corporeal ex-vivo applications.
  • the IgE-bearing B cells in the circulation of the patients can be removed by an affinity matrix (antibody immobilized on a solid phase) which is conjugated with these mAbs.
  • TESC-2 is also preferred for in vivo use because it is a humanized antibody, and it therefore less immunogenic than the wholly murine mAb TES-C21.
  • Such humanized mAbs are less likely to evoke an immune or allergic response. It is noted that such a response could deplete the antibodies which are administered before such antibodies could function to bind to the secreted or membrane-bound forms of IgE, thereby reducing the
  • the mAbs TES-C21 and TESC-2 can also be used as carrier agents of cytotoxic drugs or for delivering an effector substance, by conjugating the mAbs to these substances.
  • a toxin-antibody conjugate will bind and directly kill B cells producing IgE, but not B cells producing other isotypes which do not express IgE on their surfaces.
  • These toxins are cytolytic or cytotoxic agents, including cytotoxic steroids, gelonin, abrin, ricin, Pseudomonas toxin, diphtheria toxin, pokeweed antiviral peptide, tricathecums, radioactive nuclides, and membrane-lytic enzymes (such as phospholipase). The method of making these conjugates is described in International Application PCT/US88/04706.
  • the TES-C21 and TESC-2 mAbs can also be used in combination with factors which enhance ADCC, such as granulocyte monocyte-colony stimulating factor ("GM-CSF 1 ) and monocyte-colony stimulating factor ("M-CSF 1 )
  • GM-CSF 1 granulocyte monocyte-colony stimulating factor
  • M-CSF 1 monocyte-colony stimulating factor
  • Immunotherapies employing the mAbs of the invention can be used in combination with conventional desensitization immunotherapy.
  • desensitization with allergen can be performed in conjunction with the administration of either the mAbs of the invention or antibody-toxin conjugates discussed above, to down-regulate or substantially eliminate IgE producing cells.
  • Desensitization induces IgG production against the allergen/immunogen. Inducing such IgG production may be most effective as an allergy therapy when IgE-producing B cells are substantially depleted.
  • the combination of antibody and desensitization therapy is attractive because although the IgE-producing B cells may only be temporarily depleted (for a few weeks or months) by the mAbs of the invention, and will eventually re-populate, the desensitization effect may last much longer.
  • the TES-C21 and TESC-2 mAbs can also be used in making anti-
  • the TES-C21 and TESC-2 mAbs can also be used in making derivative antibodies which draw cytotoxic cells such as macrophages or cytotoxic T cells toward the targeted IgE-expressing B cells.
  • These derivative antibodies which are useful in allergy therapy, include bi-specific antibodies having a specificity for a receptor of a cytotoxic cell and a specificity for the IgE expressing cells.
  • Such hybrid bi-specific antibodies can include two different Fab moieties, one Fab moiety having antigen specificity for the targeted B cells, and the other Fab moiety having antigen specificity
  • the bi- specific antibodies of the invention can be a single antibody having two specificities, or a heteroaggregate of two or more antibodies or antibody fragments. See, e.g.. C. Reading, U.S. Patent Nos. 4,474,893 and 4,714,681;
  • the mAbs TES-C21 and TESC-2 are made by techniques well-known in the art, which are described in International Application No.
  • mice Male Balb/c mice were immunized several times with polyclonal human IgE from sera (provided by Ventrex), where the IgE was combined with a suitable adjuvant. Mice were sacrificed after the last injection of immunogen and the spleens were removed for preparing single cell suspensions for fusion with myeloma cells. The spleen cells were fused with Sp2/0 cells using a fusion mixture of polyethylene glycol 1450 (Kodak),
  • hybridomas resulting from the fusion were then screened by enzyme-linked immunosorbent assay (ELISA) against human IgE bound to an Immulon 2 plate.
  • ELISA enzyme-linked immunosorbent assay
  • Sp 2/0 cells were co-transfected with the variable regions of TES-C21 H and L-chains,
  • the transfectoma cells were adapted to growth in serum-free medium.
  • TESC-2 was then purifed from medium of confluent cultures using an immobilized protein A column.
  • the hybridoma cell line producing the mAb TESC-2 was deposited pursuant to the Budapest treaty at the American
  • the mAb TES-C21 was found, on testing by ELISA, to be specific for human IgE, and not to react with IgG, IgM, IgA, IgD, human serum albumin, transferrin or insulin.
  • TES-C21 bound equally well to various human IgE molecules.
  • TES-C21 bound to the IgE-secreting cell lines SKO- 007, U266 and SE44 in a dose-dependent manner. But TES-C21 did not bind to human B cell lines bearing surface IgM, IgD, IgG, or IgA, or to a T cell line or to the parent murine cell line of SE44, or to a murine cell line secreting chimeric human IgG.
  • TES-C21 does not bind to IgE on low affinity FceRII receptors, and does not induce histamine release from freshly prepared human blood basophils, on which the FceR are armed with IgE. At 10 ⁇ g/ml TES-C21 is able to inhibit completely the binding of IgE to FceRII.
  • TESC-2 and TES-C21 bind equally well to IgE bound to microtiter plates by binding to antigen.
  • Immulon 2 plates were coated with gpl20 peptide-ovalbumin conjugate and IgE-SE44 was bound to the immobilized antigen.
  • TES-C21 or TESC-2 at the concentrations in Fig.
  • TESC-2 and TES-C21 have the same relative affinity for IgE bound to microtiter plates by binding to antigen. Immulon
  • TES-C21 was detected using horseradish peroxidase-conjugated streptavidin.
  • TESC-2 and TES-C21 bind equally to IgE-secreting cells, as shown in Fig. 3.
  • Cells were incubated at 2 x 10 6 cells/lOO l PBS-1% goat serum in the indicated antibody concentrations at 0° for 30 min. Binding of TES-
  • FITC intensity gate was set to yield 10% ⁇ 0.5% positive cells in the absence of primary immunoglobulins.
  • the data shown in Fig. 3 represents the net increase in percent positive cells.
  • IM-9 IgG-secreting human lymphoblastoid line
  • both chimeric TESC-2 and murine TES-C21 inhibit binding of IgE to FceRII.
  • the mAb were preincubated at the indicated
  • HEM7 is a control mAb that does not bind to serum IgE and does not affect IgE binding to FceRII.
  • TESC-2 or FITC goat anti-human IgE (with TES-C21).
  • TESC-2 nor TES-C21 induces histamine release from freshly prepared human blood basophils, on which the FceR are armed with IgE. Due to the variable release of mediators from basophils of different donors, the mAbs were examined at multiple concentrations on basophil preparations from multiple donors. No induction of histamine release by TESC-2 or TES-C21 was observed.
  • TES-C21 did not induce histamine under these very permissive conditions.
  • TESC-2 was further tested to determine whether it could block the binding of IgE to FceRI receptors, and whether immune complexes of IgE and TESC-2 would bind to these receptors.
  • TESC-2 inhibits the binding of human IgE to FceRI
  • human peripheral blood basophils that had been depleted of IgE by treatment at low pH were reloaded or sensitized with SE44-derived chimeric IgE reactive to a peptide antigen.
  • Functional binding of SE44 IgE was tested by histamine release induced by the polyvalent R15K peptide-ovalbumin conjugate to which the variable region of IgE-SE44 binds.
  • IgE-SE44 was not preincubated 37 66 with TESC-2
  • IgE-SE44 was preincubated with 3 68
  • TESC-2 IgE-SE44 was preincubated with 0 63

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à l'anticorps monoclonal murin (mAb) TES-C21 et à l'mAb murin/humain chimérique TESC-2, dont les régions variables sont dérivées du TES-C21 et qui comporte des régions constantes humaines (gamma1,kappa). Ces deux anticorps TES-C21 et TESC-2 se lient spécifiquement à l'IgE et ne sont pas réactifs avec d'autres isotypes à chaînes lourdes. Ces deux anticorps mAb se lient spécifiquement aux lymphocytes B sécrétant l'IgE et ne réagissent pas avec d'autres types de cellules leucocytaires. Aucun de ces deux anticorps ne se lie à l'IgE liée au récepteur FcepsilonRII et ces deux anticorps mAb empêchent la liaison de l'IgE au récepteur FcepsilonRII de faible affinité se trouvant sur les lymphocytes B. Aucun de ces anticorps mAb n'induit la libération de l'histamine des leucocytes basophiles humains. L'anticorps TESC-2 empêche la liaison de l'IgE aux leucocytes basophyles. Ces propriétés rendent les anticorps mAb utilisables en particulier dans le traitement des allergies chez l'homme.
EP9292901974A 1991-03-26 1992-10-22 Monoclonal antibodies which bind to secreted and membrane-bound ige, but not to ige on basophils Withdrawn EP0585224A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1991/001991 WO1992017207A1 (fr) 1991-03-26 1991-03-26 ANTICORPS MONOCLONAUX QUI SE LIENT A L'IgE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IgE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES

Publications (2)

Publication Number Publication Date
EP0585224A1 true EP0585224A1 (fr) 1994-03-09
EP0585224A4 EP0585224A4 (en) 1994-09-14

Family

ID=22225411

Family Applications (1)

Application Number Title Priority Date Filing Date
EP9292901974A Withdrawn EP0585224A4 (en) 1991-03-26 1992-10-22 Monoclonal antibodies which bind to secreted and membrane-bound ige, but not to ige on basophils

Country Status (2)

Country Link
EP (1) EP0585224A4 (fr)
WO (1) WO1992017207A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452542A3 (fr) * 1992-09-24 2007-05-02 Novartis AG Anticorps monoclonaux humains transformés contre l'IgE
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
WO1997010004A1 (fr) * 1995-09-13 1997-03-20 Genentech, Inc. Procedes de traitement de la cystite interstitielle
DE19643427C1 (de) * 1996-10-22 1998-02-12 Bundesrep Deutschland Verfahren zur Bestimmung von Allergenen in der Luft
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
CN1289253A (zh) * 1998-01-29 2001-03-28 泰诺士公司 以lgE拮抗剂治疗特应性皮炎
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
WO2004070010A2 (fr) * 2003-02-01 2004-08-19 Tanox, Inc. Procede destine a produire des anticorps a affinite elevee
SI2335725T1 (sl) 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
UA102994C2 (ru) 2007-03-22 2013-09-10 Дженентек, Инк. АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ
MX2009010765A (es) * 2007-04-02 2009-10-26 Amgen Fremont Inc Anticuerpos anti-ige.
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
SI2494356T1 (sl) 2009-10-26 2017-07-31 Genentech, Inc. Preizkusi za detektiranje protiteles, specifičnih za terapevtska protitelesa proti IgE, in njihova uporaba pri anafilaksi
KR101413689B1 (ko) * 2010-11-15 2014-07-01 한국생명공학연구원 인간 ｔｅｓｃ 단백질에 특이적으로 결합하는 단일클론항체 및 이의 용도
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
CN105722539B (zh) 2013-11-13 2021-01-15 豪夫迈·罗氏有限公司 辅助式手动注射装置和方法
CA3226165A1 (fr) 2018-02-09 2019-08-15 Genentech, Inc. Procedes therapeutiques et de diagnostic pour des maladies inflammatoires mediees par des mastocytes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006138A1 (fr) * 1987-12-31 1989-07-13 Tanox Biosystems, Inc. Epitopes antigeniques uniques sur des lymphocytes b porteurs d'immunoglobuline e
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
EP0396505A2 (fr) * 1989-05-04 1990-11-07 Ciba-Geigy Ag Anticorps monoclonaux spécifiques pour un isotype d'immunoglobuline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4865980A (en) * 1982-12-29 1989-09-12 University Of Hawaii Monoclonal antibodies for DNA-RNA hybrid complexes and their uses
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
GB2160312B (en) * 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
US5026545A (en) * 1984-09-17 1991-06-25 Baxter International, Inc. Treatment of allergy and composition therefor
US5017489A (en) * 1985-06-28 1991-05-21 Massachusetts Institute Of Technology Cytotoxic T lymphocte serine esterase and method for stimulation and inhibition
US4714759A (en) * 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
WO1989006138A1 (fr) * 1987-12-31 1989-07-13 Tanox Biosystems, Inc. Epitopes antigeniques uniques sur des lymphocytes b porteurs d'immunoglobuline e
EP0396505A2 (fr) * 1989-05-04 1990-11-07 Ciba-Geigy Ag Anticorps monoclonaux spécifiques pour un isotype d'immunoglobuline

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIO/TECHNOLOGY vol. 8, no. 2 , February 1990 , NEW YORK NY, USA pages 122 - 126 T. CHANG ET AL. 'Monoclonal antibodies specific for human IgE-producing B cells: A potential therapeutic for IgE-mediated allergic diseases.' *
See also references of WO9217207A1 *
THE FASEB JOURNAL vol. 4, no. 7 , 26 April 1990 , BETHESDA MD, USA page A1808 F. DAVIS ET AL. 'Monoclonal antibodies specific for the transmembrane anchor peptide og IgE.' *
THE FASEB JOURNAL vol. 5, no. 4 , 11 March 1991 , BETHESDA MD, USA page A605 F. DAVIS ET AL. 'Two isoforms of membrabe-bound human IgE.' *
THE JOURNAL OF CELL BIOLOGY vol. 109, no. 4(2) , October 1989 , NEW YORK NY, USA page 163A F. DAVIS ET AL. 'Monoclonal antibodies that bind to IgE on B cells but not to IgE on high and low affinity IgE receptors.' *
THE JOURNAL OF CELL BIOLOGY vol. 109, no. 4(2) , October 1989 , NEW YORK NY, USA page 164A L. GOSSETT ET AL. 'Reactivity of IgE on FcepsilonRII with various IgE-specific monoclonal antibodies.' *

Also Published As

Publication number Publication date
EP0585224A4 (en) 1994-09-14
WO1992017207A1 (fr) 1992-10-15

Similar Documents

Publication Publication Date Title
EP0585224A1 (fr) ANTICORPS MONOCLONAUX QUI SE LIENT A L'IgE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IgE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES
US5543144A (en) Treating hypersensitivities with anti-IGE monoclonal antibodies which bind to IGE-expressing B cells but not basophils
Chang et al. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases
JP3360108B2 (ja) 二つのエフェクター機能を有する二元特異性異種抗体
US5342924A (en) Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
Davis et al. Can anti-IgE be used to treat allergy?
KR100584051B1 (ko) 알레르기에 대한 백신 접종 및 치료를 위한 펩티드임뮤노겐
US5428133A (en) Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
US5614611A (en) Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5422258A (en) Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
JP3449712B2 (ja) ヒトε免疫グロブリン固定ペプチドの細胞外部分及びそれに特異的な抗体
US5254671A (en) Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
WO1992007574A1 (fr) Glycoproteines associees a des immunoglobulines a liaison membranaire et utilisees comme cibles anticorpales sur des cellules b
EP1004312A1 (fr) Procédé pour le traitement de sclérose en plaques
US5298420A (en) Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
JPH01501201A (ja) 抗体
WO1989006967A1 (fr) Immunosuppresion a l'aide de compositions d'immunotoxines de cellules t anti-pan
US20040081649A1 (en) Treating Atopic dermatitis with IgE antagonists
USRE42324E1 (en) Compound for treatment of allergy and asthma
Dillon Vasculitis treatment–new therapeutic approaches
WO1999038531A1 (fr) TRAITEMENT DE LA DERMATITE ATOPIQUE A L'AIDE D'ANTAGONISTES D'IgE
EP0550544B1 (fr) Conjugues antigenes-anticorps
US20020006402A1 (en) Administering IgE antagonists during pregnancy to ameliorate allergic diseases in the offspring
Harpprecht et al. Human Monoclonal Antibody against Human Lymphocytic Cells: A Human Monoclonal Antibody that Reacts Preferentially with Human Lymphocytic Cells
Williams et al. Autoantibodies as chameleons

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/13

A4 Supplementary search report drawn up and despatched

Effective date: 19940728

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19961029